

ABBOTT LABORATORIES  
Form 8-K  
July 06, 2009

## UNITED STATES

## SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

July 6, 2009

Date of Report (Date of earliest event reported)

## ABBOTT LABORATORIES

(Exact name of registrant as specified in its charter)

---

**Illinois**

(State or other Jurisdiction  
of Incorporation)

**1-2189**

(Commission File Number)

**36-0698440**

(I.R.S. Employer  
Identification No.)

---

100 Abbott Park Road

Edgar Filing: ABBOTT LABORATORIES - Form 8-K

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(847) 937-6100**

**Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:**

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective August 1, 2009, Olivier Bohuon, Senior Vice President, International Pharmaceuticals, has been named Executive Vice President, Pharmaceutical Products, succeeding James L. Tyree. Tyree will transition to a new role as President, Abbott Biotech Ventures Inc., a subsidiary focused on investments in early stage pharmaceuticals and biologics.

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Abbott Laboratories**

Date: July 6, 2009

By: */s/ Thomas C. Freyman*  
Thomas C. Freyman  
Executive Vice President,  
Finance and Chief Financial Officer